Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say.Investors Business Daily • 11/03/26
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 10/29/26
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 10/29/26
Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?24/7 Wall Street • 10/29/26
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026PRNewsWire • 10/27/26
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug RevenueThe Motley Fool • 10/27/26
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/27/26
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?The Motley Fool • 10/27/26
TCW Concentrated Large Cap Growth Fund Q3 2026 Winners, Laggards, Buys & SellsSeeking Alpha • 10/27/26
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress TranscriptSeeking Alpha • 10/24/26
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?The Motley Fool • 10/24/26
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancerCNBC • 10/24/26
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPRNewsWire • 10/24/26